Clinical trials: Influenza Type A
Influenza
Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in healthy adult and elderly populations.
- Trial name
- NCT00943631
- Testing
- Inactivated H1N1 Vaccine
- Where
- 3 sites in United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A
Biomarkers Predicting Infectivity in an Experimental Human Influenza Model
This study aims to test the hypothesis that gene transcriptional changes occur within 24 hours of virus exposure in the blood and nasal mucosa, and to identify early biomarker signatures that are predictive of higher viral…
- Trial name
- PRESAGE (NCT03207152)
- Testing
- Influenza A/California/04/09
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Duke University
Novel Influenza A/H1N1
Surveillance for Adverse Events Following Pandemic H1N1 Immunization
Influenza vaccines are continuously modified to adjust to the virus antigenic shifts or drifts, and its safety profile may vary.
- Trial name
- NCT01289418
- Volunteers
- 6,525 people, healthy volunteers welcome
- Sponsor
- PHAC/CIHR Influenza Research Network
Influenza
GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE
This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-55 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a…
- Trial name
- GERMINATE (NCT06620185)
- Testing
- FLUENZ, Influenza challenge virus
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Influenza Due to Influenza A Virus Subtype H5N2
Safety and Immunogenicity of Live Attenuated Influenza H5N2
The purpose of this study is to evaluate immune response and safety of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO, Thailand in healthy Thais.
- Trial name
- NCT01841918
- Testing
- Avian Flu Vaccine
- Where
- Thailand
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Haemophilus Influenzae, Haemophilus Influenzae Type a
Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine
This study is testing a vaccine designed to protect against Haemophilus influenzae type a (Hia), a bacterium that can cause serious infections.This is a phase 2 trial.
- Trial name
- NCT07743008
- Testing
- Haemophilus influenzae serotype a vaccine candidate
- Where
- 2 sites in Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- InventVacc Biologicals Inc.
Influenza
Novartis H1N1 Vaccine in Pregnant Women
The purpose of this study is to evaluate the safety of a 2009 H1N1 influenza vaccine in pregnant women and to determine how their body reacts to different strengths of the vaccine.
- Trial name
- NCT00992719
- Testing
- Inactivated H1N1 Vaccine
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to…
- Trial name
- NCT07516418
- Testing
- H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3
- Where
- 6 sites in Australia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza A
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
- Trial name
- PANDA (NCT07128615)
- Testing
- AZD4117, AZD5315
- Where
- 14 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Influenza A
Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults
This study will evaluate the safety and immunogenicity of FP-01.1 and FP-01.1 reformulated with an adjuvant (FP-01.1-Adjuvant) in relatively healthy subjects 65 to 74 years of age, subjects that are more representative of the…
- Trial name
- NCT01701752
- Testing
- FP-01.1 + TIV, FP-01.1-Adjuvant + TIV, Adjuvant + TIV
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Immune Targeting Systems Ltd
Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine
Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants
The objective of this study is to describe the safety and immunogenicity of a non-adjuvanted vaccine against pandemic influenza A (H1N1)in patients with chronic and or immunocompromised disease, elderly and pregnants.
- Conditions
- Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine, Immunogenicity of Pandemic Influenza A (H1N1)Vaccine
- Trial name
- NCT01218685
- Testing
- Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS
- Where
- Brazil
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Haemophilus Influenza
A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine
Haemophilus influenza type b (Hib) remains a serious global health threat associated with high mortality and morbidity in young children.
- Trial name
- NCT02692859
- Testing
- Hib conjugate vaccine
- Volunteers
- 1,992 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
H7N9 Boost in Healthy Adults
The study will be an open-label phase 2 clinical trial of a single dose of an inactivated H7N9 influenza vaccine (non-adjuvanted).
- Trial name
- NCT02586792
- Testing
- Monovalent influenza A/H7N9 virus vaccine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diphtheria, Tetanus
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants
This is a study to compare the safety and immune response of a pentavalent DTaP-HB-PRP~T combined vaccine with Tritanrix-HepB/Hib™, when both are given concomitantly with OPV at 6, 10, and 14 weeks of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00348881
- Testing
- DTaP-HB-PRP~T combined vaccine, Tritanrix-HepB/Hib™ vaccine, Oral poliomyelitis vaccine (OPV)
- Where
- 4 sites in Philippines
- Volunteers
- 2,133 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
The purpose of this study is to characterize the immunogenicity and safety of 3 doses of GSK's avian flu vaccine GSK 1557484A given at different time intervals to adults aged 18 years or greater who are at increased occupational…
- Trial name
- NCT01045564
- Testing
- GSK influenza virus H5N1 vaccine 1557484A
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
H5N1 Influenza, H5N1 Virus
Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
Given the recent circulation of avian influenza A(H5N1) clade 2.3.4.4b strains in birds and mammals in North America, Canada procured a supply of Arepanrix™ H5N1 for potential use in persons at high risk of highly pathogenic…
- Conditions
- H5N1 Influenza, H5N1 Virus, Avian Influenza, Avian Influenza A Virus
- Trial name
- NCT07275060
- Testing
- H5N1 vaccine (Arepanrix)
- Where
- 4 sites in Canada
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
Influenza
Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People
Background: Researchers want to know if a certain type of antibody in the blood affects whether people get influenza (the flu). They will study 2 different groups with different levels of anti-HA antibodies and expose them to the…
- Trial name
- NCT01971255
- Testing
- Ca/04/2009/H1N1r Challenge Virus
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A Virus Infection, Swine Flu
A Pilot Study for Collection of Anti-Influenza A Immune Plasma
Background: The influenza A virus can cause infections that lead to fever, cough, muscle aches, diarrhea, and headaches, and can even be fatal in some people.
- Trial name
- NCT00984451
- Testing
- Plasma collection following infection or vaccination with influenza A
- Where
- 12 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Influenza A
MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study
The purpose of this study is to evaluate the usability of the MGC Health COVID-19 \& Flu A+B Home Multi Test in home use.
- Conditions
- COVID-19, Influenza A, Influenza B
- Trial name
- NCT05732610
- Testing
- MGC Health COVID-19 & Flu A+B Home Multi Test, MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medical Group Care, LLC
Covid19, Influenza A
Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19
The outbreak of the novel coronavirus SARS-CoV-2 caused a health emergency of international proportions when it was declared by the World Health Organization (WHO) in January 2020.
- Conditions
- Covid19, Influenza A, Respiratory Disease
- Trial name
- AtemNHK (NCT04653727)
- Testing
- Cross-sectional survey
- Where
- Germany
- Volunteers
- 1,287 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany